Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside.
Explore this paper's citation graph
Summary
The combination of doripenem and an aminoglycoside may be an effective treatment of infections caused by P. aeruginosa with elevated carbapenem MIC values with lower risk of selecting further resistance.
- Type
- article
- Published
- 2006-07-01
- Cited by
- 34
- References
- 12
- OpenAlex
- https://openalex.org/W16725297
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:35802625
Keywords
Philosophy, Political science
References
- [Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
- Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard
- Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard
- Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
- In Vitro and In Vivo Antibacterial Activities of S-4661, a New Carbapenem
- Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
- Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
- Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas.
- Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
- Activities of Doripenem (S-4661) against Drug-Resistant Clinical Pathogens
- Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Cited by
- Studies of Pseudomonas aeruginosa and its virulence factors in a mouse model of dermal infection
- New developments in carbapenems.
- Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens
- In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United States
- A Review of Doripenem for the Treatment of Serious Bacterial Infections
- Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.
- Multidrug-Resistant Gram-Negative Infections
- Doripenem
- P2088 Variations and trends in the activity of doripenem and other broad-spectrum agents against leading bacterial pathogens: results from a European Surveillance Program (2003–2006)
- STABILITY INDICATING ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR THE SIMULTANEOUS ESTIMATION OF DORIPENEM AND ITS DEGRADATION PRODUCTS
- Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
- Determination of doripenem and related substances in medicinal product using capillary electrophoresis.
- The role of carbapenems in the treatment of severe nosocomial respiratory tract infections
- The Use of Carbapenems in the Treatment of Serious Infections
- Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study.
- β-lactams against emerging ‘superbugs’: progress and pitfalls
- Characteristics of doripenem: a new broad-spectrum antibiotic
- Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
- Doripenem for Injection
- Doripenem: a new addition to the carbapenem class of antimicrobials.
Related papers
No related papers recorded.